Chamber630: FDA OK's Emergent BioSolutions Plant To Resume Manufacturing J&J's Covid-19 Vaccine

Press release from the Chamber630:

Aug 2, 2021

Emergent BioSolutions has FDA approval to resume its role in producing the Johnson & Johnson COVID-19 vaccine, albeit with continued oversight and inspections. “The American people should have high expectations of the partners its government chooses to help prepare them for disaster, and we have even higher expectations of ourselves,” Emergent CEO Robert Kramer says.

Full Story: CNN

This press release was produced by the Chamber630. The views expressed here are the author’s own.